Table 4c.
Risk classification for first postoperative plasma NGAL after addition to clinical model
| Clinical Model | Clinical Model + Plasma NGAL |
Total | ||
|---|---|---|---|---|
| <3% | 3% to 10% | >10% | ||
| AKI participants | ||||
| <3% | 11 (64.7%) | 6 (35.3%) | 0 (0%) | 17 |
| 3% to 10% | 2 (9.1%) | 7 (31.8%) | 13 (59.1%) | 22 |
| >10% | 0 (0%) | 6 (35.3%) | 11 (64.7%) | 17 |
| total | 13 | 19 | 24 | 56 |
| Non-AKI participants | ||||
| <3% | 456 (79%) | 121 (21%) | 0 (0%) | 577 |
| 3% to 10% | 139 (30.1%) | 248 (53.7%) | 75 (16.2%) | 462 |
| >10% | 0 (0%) | 43 (51.8%) | 40 (48.2%) | 83 |
| total | 595 | 412 | 115 | 1122 |
Clinical model is age (per year), gender, white race, CPB time > 120 minutes, nonelective surgery, preoperative eGFR, diabetes, and hypertension.